| Literature DB >> 32088086 |
Kangjie Yu1, Joseph Rohr2, Yang Liu1, Mingyang Li1, Junpeng Xu1, Kaijing Wang1, Jia Chai1, Danhui Zhao1, Yixiong Liu1, Jing Ma1, Linni Fan1, Zhe Wang3, Shuangping Guo4.
Abstract
Triple-negative breast carcinoma (TNBC) is a subtype of breast carcinoma defined by negativity for estrogen receptor (ER) or progesterone receptor (PR) by immunohistochemical analysis and negativity for human epidermal growth factor receptor (Her2) by immunohistochemistry or in situ hybridization. TNBC is clinically marked by its high aggressiveness, particularly poor outcomes including a low survival rate, and the lack of specific and effective treatments. Therefore, new potential targets for the treatment of TNBC must be identified. This review summarizes recent evidence supporting novel targets and possible therapeutic regimens in the treatment of TNBC.Entities:
Keywords: Progress in pathophysiology; Signaling pathway; Therapeutic targets; Triple negative breast carcinoma (TNBC)
Mesh：
Year: 2020 PMID： 32088086 DOI： 10.1016/j.prp.2020.152874
Source DB: PubMed Journal: Pathol Res Pract ISSN： 0344-0338 Impact factor: 3.250